QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

Website: qedtx.com

Employees: 100 - 249

HQ: 650-231-4088

Location: Palo Alto, CA, US

Revenue: 10 - 20 Million

N/A

QED Therapeutics Technologies

Captcha

reCAPTCHA

Email Providers

Outlook

Load Balancers

Apache

Fonts

Google Font API

Other

Google Maps

View All Technologies Used At QED Therapeutics

Similar companies to QED Therapeutics

Shape Therapeutics Inc. BillionToOne Delta Project Management PolarityTM The River Source First Palmetto Bank SCYNEXIS Sera Prognostics Berghealth Taysha Gene Therapies SRQ bio CBS Labs SwanBio Therapeutics craresources AES Krystal Biotech, Inc. CorneaGen First Alternative Therapies Sanguine BioSciences Skyhawk Therapeutics

Contacting QED Therapeutics: Connect with Executives and Employees

Get in Touch with QED Therapeutics Executives and Employees

Connecting with QED Therapeutics's Executives and Workforce

Accessing Contact Information for QED Therapeutics Executives

Connecting with QED Therapeutics: Reach Out to Their Team

Discover How to Contact QED Therapeutics Executives and Staff

Looking to connect with QED Therapeutics executives or employees?

Seeking to Get in Touch with QED Therapeutics Executives or Staff?

Want to Reach Out to QED Therapeutics Executives or Team Members?

In Search of Contact Details for QED Therapeutics Professionals?

Connecting with QED Therapeutics: Contacting Executives and Staff

Browse companies

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z